Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetaben PET Patterns in MCI for Prediction of Conversion to Alzheimer's Disease
2015-001184-39Phase 3Completed
- Sponsor
- ASL 5 Spezzino
- Start
- Dec 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of florbetaben in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by ASL 5 Spezzino. Started Dec 2017; status: completed.
02
Drugs
florbetaben
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-001184-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001184-39.